ArticleThe Journal of clinical investigation2012
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 60 citations in OpenAlex.
- C/EBPγ interacts with C/EBPα and activates the β-catenin pathway in idiopathic pulmonary fibrosis.Cellular and molecular life sciences : CMLS · 2026Article
- A Review of CEBPA's Role in Hereditary Leukemia.EJHaem · 2026Review
- Single-cell multi-omics analysis reveals cancer regulatory elements of transcriptional programs and clinical implications.Cell death & disease · 2025Article
- CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.International journal of hematology · 2024Review
- A comprehensive analysis of CEBPA on prognosis and function in uterine corpus endometrial carcinoma.Scientific reports · 2024Article
- Human RP105 monoclonal antibody enhances antigen-specific antibody production in unique culture conditions.iScience · 2024Article
- C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.Journal of experimental & clinical cancer research : CR · 2024Article
- Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation.Nature communications · 2023Article
- CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer.Journal of translational medicine · 2023Article
- Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.Blood reviews · 2023Review
- Small Extracellular Vesicles and Their Involvement in Cancer Resistance: An Up-to-Date Review.Cells · 2022Review
- CCAAT enhancer binding protein gamma (C/EBP-γ): An understudied transcription factor.Advances in biological regulation · 2022Review
- CEBPG promotes acute myeloid leukemia progression by enhancing EIF4EBP1.Cancer cell international · 2021Article
- CEBPγ facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation.Cancer science · 2021Article
- An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.Frontiers in molecular biosciences · 2021Article
- Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.Journal of gynecologic oncology · 2020Article
- Activating transcription factor 3 coordinates differentiation of cardiac and hematopoietic progenitors by regulating glucose metabolism.Science advances · 2020Article
- CEBPG promotes esophageal squamous cell carcinoma progression by enhancing PI3K-AKT signaling.American journal of cancer research · 2020Article
- Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.Science advances · 2019Article
- Identification of cancer omics commonality and difference via community fusion.Statistics in medicine · 2019Article
Corrections and comments
- Commented on by
- Erratum issuedDiRuscio, Annalisa [corrected to Di Ruscio, Annalisa]
Authors and funding
19 authors at 6 institutions in 4 countries.
Funding
Abstract
C/EBPs are a family of transcription factors that regulate growth control and differentiation of various tissues. We found that C/EBPγ is highly upregulated in a subset of acute myeloid leukemia (AML) samples characterized by C/EBPα hypermethylation/silencing. Similarly, C/EBPγ was upregulated in murine hematopoietic stem/progenitor cells lacking C/EBPα, as C/EBPα mediates C/EBPγ suppression. Studies in myeloid cells demonstrated that CEBPG overexpression blocked neutrophilic differentiation. Further, downregulation of Cebpg in murine Cebpa-deficient stem/progenitor cells or in human CEBPA-silenced AML samples restored granulocytic differentiation. In addition, treatment of these leukemias with demethylating agents restored the C/EBPα-C/EBPγ balance and upregulated the expression of myeloid differentiation markers. Our results indicate that C/EBPγ mediates the myeloid differentiation arrest induced by C/EBPα deficiency and that targeting the C/EBPα-C/EBPγ axis rescues neutrophilic differentiation in this unique subset of AMLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.